

CURRICULUM VITAE

HERNANDO ZEGARRA, MD

OFFICE ADDRESSES

Retina Associates of Cleveland, Inc.
690 White Pond Drive, Suite 120; Akron, Ohio 44320
4690 Munson Street NW; Canton, Ohio 44718
3401 Enterprise Parkway, Suite 300; Cleveland, Ohio 44122
650 Graham Road, Suite 103/104; Cuyahoga Falls, Ohio 44221
340 Oxford Street, Suite 210; Dover, Ohio 44622
6100 South Broadway Avenue, Suite 200; Lorain, Ohio 44052
3591 Reserve Commons Drive; Medina, Ohio 44256
9485 Mentor Avenue, Suite 211; Mentor, Ohio 44060
15299 Bagley Road, Suite 200; Cleveland, Ohio 44130
17534 Royalton Road, Suite 201; Strongsville, Ohio 44136
170 North Road NE; Warren, Ohio 44483
4350 Crocker Road, Suite 200; Westlake, Ohio 44145
5390 Belmont Avenue; Youngstown, Ohio 44505

TELEPHONE

216-831-5700

WEBSITE

www.retina-doctors.com

EDUCATION

Medical School Cayetano Heredia University
Lima, Peru
1968, MD

POSTGRADUATE TRAINING

Internship Loayza Hospital
(Peru) Lima, Peru
April 1967 to March 1968

Residency Ophthalmology
(Peru) Cayetano Heredia University
Lima, Peru
April 1968 to March 1969

Internship Rotating internship
(United States) Grasslands Hospital (now Westchester Medical Center)
Valhalla, New York
July 1969 to June 1970

- Fellowship* Retinal fluorescein angiography
Cleveland Clinic Foundation, Department of Ophthalmology
Cleveland, Ohio
July 1970 to June 1971
- Residency*
(United States) Ophthalmology
Cleveland Clinic Foundation, Department of Ophthalmology
Cleveland, Ohio
July 1971 to June 1974
- Fellowship* Ophthalmic and Retinal Diseases and Surgery
Devers Eye Clinic of Good Samaritan Hospital
Portland, Oregon
July 1974 to September 1975

LICENSURE AND BOARD CERTIFICATION

Licensed to practice medicine in Ohio

Diplomate, American Board of Ophthalmology, 1977

PROFESSIONAL POSITIONS

Retina Associates of Cleveland, 1989–

Practice limited to retinal diseases and surgery. Associates: Lawrence J. Singerman, MD; Michael A. Novak, MD; Z. Nicholas Zakov, MD; Scott D. Pendergast, MD; David G. Miller, MD; Joseph M. Coney, MD; Jerome P. Schartman, MD; Llewelyn J. Rao, MD; Arnold F. Nothnagel, DO; Shawn A. Lewis, MD; Sean M. Platt, MD; Matthew K. Adams, MD, MBA

Director, Electrophysiology and Fluorescein Angiography Laboratories, October 1975 to December 1988

Cleveland Clinic Foundation, Department of Ophthalmology, Retina Service
Cleveland, Ohio

HONORS AND AWARDS

Charter Member, Retina Hall of Fame, 2017

Best Doctors in America, 2009-2019

MEMBERSHIPS

American Academy of Ophthalmology

American Medical Association

American Society of Retinal Specialists (formerly the Vitreous Society)

Association for Research in Vision and Ophthalmology
Cleveland Academy of Medicine
Cleveland Ophthalmological Society
Colombian Ophthalmology Society (Honorary Member)
Diabetes Association of Greater Cleveland
Latin American Group on Ocular Angiography and Photocoagulation
Ohio State Medical Association
Pan-American Ophthalmological Society
Peruvian Ophthalmological Society
Peruvian-American Medical Society
Retina Society

HOSPITAL AFFILIATIONS

Hillcrest Hospital; Cleveland, Ohio
Summa Health; Akron, Ohio

RESEARCH ACTIVITIES

NIH-funded Grants

Home vision monitoring in AREDS2 for progression to neovascular age-related macular degeneration

Co-investigator, 2011–2013

Comparison of age-related macular degeneration treatments trials: Lucentis-Avastin trial (CATT)

Co-investigator, 2008–2012

Age-Related Eye Disease Study 2 (AREDS2)

Co-investigator, 2006–2012

*Standard Care vs. **C**orticosteroid for **R**etinal Vein Occlusion (SCORE) Study*

Co-investigator, 2004–2009

Complications of Age-related Macular Degeneration Prevention Trial (CAPT)

Co-investigator, 1999–2006

Epidemiology of Diabetes Interventions and Complications Trial (EDIC), National Institutes of Health Grant

Co-investigator, 1994–

Central Vein Occlusion Study (CVOS) Electrophysiology Ancillary Study

Principal investigator, 1990–1992

Endophthalmitis Vitrectomy Study

Co-investigator, 1989–1994

Macular Photocoagulation Studies

Co-investigator, 1989–1993

Central Vein Occlusion Study

Co-investigator, 1988–1993

Collaborative Ocular Melanoma Study

Co-investigator, 1987–2003

Other National Clinical Trials

Phase III, Randomized double-masked, sham controlled study to compare APL-s VS sham in patients with GA secondary to AMD (Apellis-Derby)

Co-investigator, 2019-

Phase III, A multicenter, sham-controlled, randomized, double-masked study assessing the efficacy and safety of intravitreal injects of 44 microns DE-109 for the treatment of active, non-infectious uveitis of the posterior segment (LUMINA)

Co-investigator 2019-

Phase III randomised, double-masked, parallel group, multicentre study to compare the efficacy, safety, pharmacokinetics and immunogenicity between SB11 and Lucentis in subjects with neovascular age-related macular degeneration

Principal investigator, 2018–

Randomized, double masked, uncontrolled, multicenter phase I/II study to evaluate safety and tolerability of PAN-90806 eye drops, suspension in treatment-naïve participants with neovascular age-related macular degeneration (AMD)

Co-investigator, 2018–

Phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema (YOSEMITE)

Co-investigator, 2018–

Two-year, three-arm, randomized, double-masked, multicenter, phase iii study assessing the efficacy and safety of brolicizumab versus aflibercept in adult patients with visual impairment due to diabetic macular edema (KESTREL)

Co-investigator, 2018–

Phase 2b randomized, double-masked, controlled trial to assess the safety and efficacy of intravitreal administration of Zimura™ (anti-c5 aptamer) in subjects with geographic atrophy secondary to dry age-related macular degeneration

Co-investigator, 2018–

Phase 2 double-masked, placebo-controlled study to assess the safety and efficacy of subcutaneously administered AKB-9778 15 mg once daily or 15 mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy (TIME-2b study)

Co-investigator, 2017–

Effect of LY3202626 on Alzheimer's disease progression as measured by cerebral ¹⁸F-AV-1451 Tau-PET in mild Alzheimer's disease dementia

Co-investigator, 2017–

Phase III multicenter randomized, sham controlled, study to determine the safety and efficacy of Renexus® in macular telangiectasia type 2 (NTMT-03-A)

Co-investigator, 2017–

Efficacy and safety study of squalamine ophthalmic solution in subjects with neovascular AMD (MAKO)

Co-investigator, 2016–

Phase II, multicenter, randomized, single-masked, sham-controlled study of safety, tolerability and evidence of activity of intravitreal APL-2 therapy in patients with geographic atrophy (GA)

Co-investigator, 2015–2018

Phase III double masked study of safety and efficacy of abicipar pegol in patients with neovascular age-related macular degeneration

Co-investigator, 2015–

Randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH258 versus aflibercept in subjects with neovascular age-related macular degeneration

Co-investigator, 2015–2018

Phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration (PROXIMA)

Co-investigator, 2015–2018

An 18-month Phase 2a open label, randomized study of Avastin, Lucentis, or Eylea (anti-VEGF therapy) administered in combination with Fovista (anti-PDGF BB pegylated aptamer)

Co-investigator, 2015–2017

A study of lampalizumab intravitreal injections administered every two weeks or every four weeks to patients with geographic atrophy (EXPOSURE)

Co-investigator, 2015–2017

Phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista (anti PDGF-B pegylated aptamer) administered in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy in subjects with subfoveal neovascular age-related macular degeneration

Co-investigator, 2015–2017

LHA510 proof-of-concept study as a maintenance therapy for patients with wet age-related macular degeneration

Co-investigator, 2015–2016

A study investigating the efficacy and safety of lampalizumab intravitreal injections in patients with geographic atrophy secondary to age-related macular degeneration (CHROMA)

Co-investigator, 2014–2018

Phase 2, multi-center study to compare the efficacy and safety of a chemokine CCR2/5 receptor antagonist with ranibizumab in adults with diabetic macular edema

Co-investigator, 2014–2016

Phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista (anti PDGF-B pegylated aptamer) administered in combination with Lucentis compared to Lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration

Co-investigator, 2013–2017

Phase 2b/3 multicenter, randomized, double-masked, dose-ranging study comparing the efficacy and safety of emixustat hydrochloride (ACU-4429) with placebo for the treatment of geographic atrophy associated with dry age-related macular degeneration (SEATTLE)

Co-investigator, 2013–2016

Prospective, randomized, double-masked, multicenter, two arm study comparing the efficacy and safety of ESBA1008 versus Eylea® in subjects with exudative age-related macular degeneration

Co-investigator, 2013–2014

Prospective, two-cohort, single-masked study to evaluate the effect of ESBA1008 applied by microvolume injection or infusion in subjects with exudative age-related macular degeneration

Co-investigator, 2013

A multicenter, randomized, sham-control, proof-of-concept study of intravitreal LFG316 in patients with geographic atrophy associated with age-related macular degeneration

Co-investigator, 2012–2015

Safety and efficacy study of gevokizumab to treat active non-infectious uveitis (EYEGUARD™-A)

Co-investigator, 2012–2015

Safety and efficacy study of gevokizumab to treat non-infectious uveitis controlled with systemic treatment (EYEGUARD™-C)

Co-investigator, 2012–2015

Efficacy and safety of squalamine lactate eye drops in subjects with neovascular (wet) age-related macular degeneration

Co-investigator, 2012–2015

Ocriplasmin for treatment for symptomatic vitreomacular adhesion including macular hole (OASIS)

Co-investigator, 2012–2014

Safety and tolerability of intravenous LFG316 in wet age-related macular degeneration

Co-investigator, 2012–2013

Single and repeat dose study of the safety and efficacy of AGN-150998 in patients with exudative age-related macular degeneration

Co-investigator, 2012

Phase 1 multicenter open-label safety and tolerability clinical trial of ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia Type 2 (Mactel)

Co-investigator, 2011–2016

A study of safety, tolerability, and evidence of activity of FCFD4514S administered monthly or every other month to patients with geographic atrophy

Co-investigator, 2011–2013

Multicenter, 2 stage (open label, dose escalation, followed by masked, randomized) single dose study of the safety and efficacy of AGN-208397 in patients with macular edema (ME) associated with retinal vein occlusion (RVO)

Co-investigator, 2011–2012

Phase 2b dose-ranging study of pazopanib eye drops versus ranibizumab intravitreal injections for the treatment of neovascular age-related macular degeneration

Co-investigator, 2010–2011

Phase 2, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) given in combination with Lucentis® in subjects with neovascular age-related macular degeneration

Co-investigator, 2010–2011

Impact of Lucentis on psychological morbidity in patients with macular edema and neovascularization secondary to retinal vein occlusion

Co-investigator, 2009–2012

Geographic Atrophy Treatment Evaluation (GATE) Study

Co-investigator, 2009–2012

Phase II, randomized, double-masked, placebo- controlled, add-on study to assess the efficacy of oral aliskiren 300 mg one daily for diabetic macular edema

Co-investigator, 2009–2010

Phase 1, single ascending dose and parallel group trial to establish the safety, tolerability, and pharmacokinetic profile of multiple intravitreal injections of Volociximab ($\alpha 5\beta 1$ integrin antagonist) as monotherapy or given in combination with Lucentis 0.5mg/eye in

subjects with neovascular AMD (Ophthotech 3000)

Co-investigator, 2008–2011

Phase 2, randomized, double-masked, placebo-controlled, dose-ranging clinical study to assess the safety and efficacy of subconjunctival injections of sirolimus in patients with diabetic macular edema secondary to diabetic retinopathy

Co-investigator, 2008–2010

Natural History of Geographic Atrophy Progression (GAP) Study

Co-investigator, 2008–2009

A study of ranibizumab injection in subjects with clinically significant with macular edema center involvement secondary to diabetes mellitus (RIDE)

Co-investigator, 2007–2012

Phase II randomized, double-masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of geographic atrophy in age-related macular degeneration (Sirion Therapeutics)

Co-investigator, 2007–2010

A multicenter, randomized, placebo-controlled, double-masked, parallel group, dose-ranging clinical trial of intravitreal microplasmin in patients undergoing surgical vitrectomy: The MIVI III (Microplasmin for Vitreous Injection III) Trial

Co-investigator, 2007–2009

A masked, multicenter, randomized, controlled trial to assess the safety and efficacy of 700 µg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of subjects with diffuse diabetic macular edema

Co-investigator, 2007–2009

Age-related Macular Degeneration: Detection of Onset of new Choroidal neovascularization (AMD DOC) study comparing preferential hyperacuity perimetry (PHP) with supervised Amsler grid in detecting AMD for earlier treatment in high-risk fellow eyes (Johns Hopkins)

Co-investigator, 2007–2009

OMEGA: A randomized, double-masked, dose-ranging, multi-center, phase II study comparing the safety and efficacy of OT-551 with placebo to treat geographic atrophy associated with age-related macular degeneration

Co-investigator, 2007–2009

COBALT: COmbining Bevasiranib And Lucentis Therapy. A phase III, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis®, compared with Lucentis® monotherapy every 4 weeks in patients with exudative age-related macular degeneration (AMD)

Co-investigator, 2007–2008

Small Interfering RNA In Macular Degeneration Study (SIRIUS): A 2 year, multicenter, randomized, controlled, masked, dose-finding trial to assess the safety and efficacy of multiple intravitreal injections of AGN211745 in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Co-investigator, 2007–2008

Phase 1, single ascending dose trial to establish the safety, tolerability, and pharmacokinetic profile of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) monotherapy and of E10030 given in combination with Lucentis 0.3mg/eye in subjects with neovascular AMD

Co-investigator, 2007

Natural history study of macular telangiectasia (MacTel)

Co-investigator, 2005–

A 6-month, Phase III, multicenter, masked, randomized, sham-controlled trial (with 6-month open-label extension) to assess the safety and efficacy of 700 µg and 350 µg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in the treatment of patients with macular edema following branch retinal vein occlusion or central retinal vein occlusion

Co-investigator, 2005–2007

A 3-year, Phase III, multicenter, masked, randomized, sham-controlled trial to assess the safety and efficacy of 700 µg and 350 µg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in the treatment of patients with diabetic macular edema.

Co-investigator, 2005–2007

RNAi Assessment of Cand5 in Diabetic Macular Edema (RACE)

Co-investigator, 2005–2007

An open label study for the evaluation of tolerability of four dose levels of Cand5 administered by single intravitreal injection in patients with wet age-related macular degeneration

Co-investigator, 2005–2007

Cand5 Anti-VEGF RNAi Evaluation (CARE): Dose comparison of Cand5 for subfoveal choroidal neovascularization associated with wet age-related macular degeneration.

Co-investigator, 2005–2007

A Phase II, dose ranging, open-labeled, multi-center study to evaluate the safety and efficacy of combretastatin A4 phosphate for treating subfoveal choroidal neovascularization in subjects with pathologic myopia

Co-investigator, 2005–2006

Protocol A43221001: A Phase 1 / 2 randomized, masked, placebo-controlled, single and multiple-dose, sequential dose escalation study of the safety and efficacy of AG-013958 in subjects with subfoveal choroidal neovascularization associated with age-related macular degeneration

Co-investigator, 2004–2006

A randomized, double-masked, placebo-controlled, parallel group, multicenter, dose-ranging study of denufosol tetrasodium (INS37217) intravitreal injection in subjects with rhegmatogenous retinal detachment

Co-investigator, 2004–2005

Ranibizumab (Lucentis) treatment in subjects with neovascular age-related macular degeneration (multiple studies)

Co-investigator, 2003–2007

The Implantable Miniature Telescope (IMT™) in patients with central vision impairment associated with age-related macular degeneration or Stargardt's macular dystrophy

Co-investigator, 2003–2005

Pegaptanib sodium (Macugen) in patients with exudative age-related macular degeneration (multiple studies)

Co-investigator, 2001–2010

Oculex Study: A Phase 2 randomized, multicenter, dose-ranging, controlled, parallel-group trial to assess the safety and effectiveness of dexamethasone posterior segment drug delivery system (DEX PS DDS®) in the treatment of persistent macular edema

Co-investigator, 1999–2008

Evaluation of anecortave acetate in patients with exudative age-related macular degeneration (multiple studies)

Co-investigator, 1999–2008

Protein Kinase C β inhibitor ruboxistaurin treatment for diabetic macular edema study and diabetic retinopathy (multiple studies)

Co-investigator, 1998–2010

Visudyne photodynamic therapy treatment of neovascular age-related macular degeneration (multiple studies)

Co-investigator, 1997–2006

SELECTED PRESENTATIONS AT LOCAL, NATIONAL, AND INTERNATIONAL MEETINGS AND SYMPOSIA

1. Treatments for retinitis pigmentosa. Optometric Retinal Update Seminar. Cleveland, Ohio, June 7, 2018

2. Non-organic visual loss. Optometric Retinal Update Seminar. Beachwood, Ohio, March 28, 2017.
3. The clinical and prognostic value of retinal images. Optometric Retinal Update Seminar. Cleveland, Ohio, June 16, 2016.
4. The clinical and prognostic value of retinal images. Featured Speaker, III International Congress of Retina and Vitreous. Lima, Peru, February 18-20, 2016.
5. Chronic conjunctivitis and choroidal folds. Optometric Retinal Update Seminar. Warren, Ohio, September 1, 2015.
6. Bilateral conjunctivitis and choroidal folds. Optometric Retinal Update Seminar. Cleveland, Ohio, June 18, 2015.
7. Retinal cases. Cleveland Clinic North Coast Retina Symposium. Cleveland, Ohio, May 15, 2015.
8. Screening for Plaquenil toxicity: the value of autofluorescence. Optometric Retinal Update Seminar. Warren, Ohio, September 16, 2014.
9. Retinal cases. Cleveland Clinic North Coast Retina Symposium. Cleveland, Ohio, May 30, 2014.
10. The progression of chloroquine and hydroxychloroquine retinal toxicity: the value of imaging. Cleveland Ophthalmological Society. Cleveland, Ohio, October 15, 2013.
11. Eylea for chronic pigment epithelial detachments (ARMD). Optometric Retinal Update Seminar. Youngstown, Ohio, September 10, 2013.
12. Retinal cases. Cleveland Clinic North Coast Retina Symposium. Cleveland, Ohio, May 22, 2013.
13. Retinal update on anti-VEGF therapy (with Drs. Coney, Miller, Novak, Schartman, and Zegarra). Ophthalmologists' Update Seminar. Vermilion, Ohio, December 20, 2012.
14. Eylea for chronic pigment epithelial detachments (ARMD). Ophthalmologists' Update Seminar. Vermilion, Ohio, August 2012.
15. 1) Co-moderator, Central serous chorioretinopathy symposium; 2) Speaker, Management of central serous chorioretinopathy. Pan-American Retina-Vitreous Society Congress and 14th GLADAOF (Grupo Latinoamericano de Angiografía y Fotocoagulación) Forum. San Jose, Costa Rica, May 18, 2012
16. The value of OCT, autofluorescence photography, and multifocal ERG in chloroquine retinopathy. Optometric Retinal Update Seminar. Beachwood, Ohio, March 15, 2012.

17. Chloroquine retinopathy. Cleveland Ophthalmological Society. Cleveland, Ohio, October 11, 2011.
18. Retinopatía toxica por cloroquina e hidroxyclozoquina (Chloroquine retinopathy). Fiftieth Anniversary of the Cayetano Heredia University Medical School. Lima, Peru, September 2011.
19. Chronic central serous choroidopathy. Optometric Retinal Update Seminar. Youngstown, Ohio, September 1, 2011.
20. Eighteen years of recurrent central serous choroidopathy. North Coast Retina Symposium. Cole Eye Institute, Cleveland Clinic Foundation, May 13, 2011.
21. Co-moderator, Medical Retina Symposium. Speaker, 1) Long-term therapy of central retinal vein occlusion with anti-VEGF agents; 2) Photodynamic therapy in the treatment of central serous choroidopathy. Croatian Ophthalmological Society. Zagreb, Croatia, October 2010.
22. Long-term therapy of central retinal vein occlusion with anti-VEGF agents. Cleveland Ophthalmological Society. Cleveland, Ohio, October 12, 2010.
23. Unilateral progressive hyperopia. Optometric Retinal Update Seminar. Beachwood, Ohio, March 25, 2010.
24. Chloroquine retinopathy. Optometric Retinal Update. Westlake, Ohio, June 18, 2009.
25. Anti-VEGF therapy for central retinal vein occlusion. Retinal Update for Ophthalmologists. Beachwood, Ohio. May 13, 2009.
26. Anti-VEGF therapy for central retinal vein occlusion. Retinal Update for Ophthalmologists. Youngstown, Ohio. March 18, 2009.
27. Retinal imaging (with DG Miller). Optometric Continuing Education Program and Open House. Lorain, Ohio. January 13, 2009.
28. Anti-VEGF therapy for central retinal vein occlusion. Retinal Update for Ophthalmologists. Youngstown, Ohio. November 20, 2008.
29. Central retinal vein occlusion: evolution in the diagnosis, management, and treatment. Optometric Retinal Update. Youngstown, Ohio. September 18, 2008.
30. Photodynamic therapy with Visudyne in the treatment of central serous retinopathy. Optometric Retinal Update. Westlake, Ohio, July 15, 2008.
31. Central serous choroidopathy: current management and new therapies. Optometric Retinal Update. Beachwood, Ohio. February 21, 2008.

32. Anti-VEGF agents in retinal disorders. Optometric Retinal Update. Westlake, Ohio. July 17, 2007.
33. The role of anti-VEGF agents in retinal disorders. Optometric Retinal Update. Mentor, Ohio. October 25, 2006.
34. Current management of retinal vein occlusion. Optometric Retinal Update. Youngstown, Ohio. September 25, 2006.
35. Current management of retinal vein occlusion. Optometric Retinal Update. Westlake, Ohio. August 9, 2006.
36. Newest information, research, and treatments for macular degeneration. Seminar on Nutrition and Macular Degeneration (joint presentation of Retina Associates of Cleveland and Macula Vision Research Foundation SupportSight). Middleburg Heights, Ohio. October 29, 2005.
37. Case review: retinal vascular and macular degenerative diseases. Optometric Retinal Update. Westlake, Ohio. August 11, 2005.
38. Pigmented fundus lesions. Optometric Retinal Update. Westlake, Ohio. July 29, 2004.
39. Unilateral retinitis pigmentosa. Optometric Retinal Update. Beachwood, Ohio. February 19, 2004.
40. Retinal case presentations and management. Optometric Continuing Medical Education. Vermilion, Ohio. December 11, 2003.
41. Unilateral retinitis pigmentosa. Optometric Retinal Update. Westlake, Ohio. August 12, 2003.
42. 1) Manejo practico de la enfermedad retinal vascular. 2) Tratamiento de la neovascularizacion coroidea con terapia fotodinamica combinada con otras modalidades terapeuticas. National Congress of Ophthalmology. Lima, Peru. July 2–6, 2002.
43. Management and prevention of retinal vascular disease. Optometric Retinal Update. Youngstown, Ohio. August 29, 2001.
44. Photodynamic therapy. Pan American Congress of Ophthalmology. Llao Llao, Argentina. July 23, 2001.
45. Management and prevention of retinal vascular disease. Ohio Optometric Association Zone 2 meeting. June 13, 2001.
46. 1) What's new in vitreoretinal diseases and surgery (Panelist). 2) Branch and central vein occlusion workshop (Instructor). 3) Manejo Práctico Actualizado de la Retina Diabética (Instructor). 4) Enfermedad Macular Tratable (Instructor). American

- Academy of Ophthalmology and the Pan-American Association of Ophthalmology. Orlando, Florida. October 24–27, 1999.
47. What's new in vitreoretinal diseases and surgery (Panelist). American Academy of Ophthalmology and the Pan-American Association of Ophthalmology. New Orleans, Louisiana. November 1998
 48. What's new in vitreoretinal diseases and surgery (Panelist). American Academy of Ophthalmology and the Pan-American Association of Ophthalmology. San Francisco, California. October 1994.
 49. Symposium on indocyanine green angiography. Latin American Group of Angiography and Laser Photocoagulation. Santiago, Chile. October 1994.
 50. 1) Symposium in retinal diseases. 2) Conference on retinitis pigmentosa and vitamin A. Fifteenth Peruvian Symposium of Ophthalmology. Lima, Peru. September 1994.
 51. Edema and retinal ischemia and retinal vascular occlusions. The Nineteenth Pan-American Congress of Ophthalmology. Caracas, Venezuela; July 1993.
 52. 1) Treatment of subfoveal choroidal neovascularization. 2) Pneumatic retinopexy. 3) Current indications and management of retinal vein occlusion. The Northwest Mexican Ophthalmology Society Annual Meeting. Tucson, Arizona; May 1993.
 53. 1) What's new in vitreoretinal diseases (Panelist). 2) Branch and central vein occlusion workshop (Instructor). 3) Discussant of two papers on choroidal neovascularization. American Academy of Ophthalmology Annual Meeting. Dallas, Texas. November 8–12, 1992.
 54. Evaluation of retinal ischemia: clinical, angiographic, and electrophysiological findings; Review of interesting fluorescein cases (coordinator). Latin American Group for Fluorescein Angiography and Laser. Cancun, Mexico. July 16–18, 1992.
 55. Acquired retinopathies simulating retinal dystrophies. Cleveland Ophthalmological Society. April 14, 1992.
 56. Ophthalmological Workshop. Ohio Academy of Family Physicians. January 11, 1992.
 57. What's new in vitreoretinal diseases (in Spanish). Senior Instructor, American Academy of Ophthalmology Annual Meeting. Anaheim, California. October 13–17, 1991.
 58. Alternative techniques to scleral buckling surgery. Case Western Reserve University Grand Rounds. Cleveland, Ohio. December 6, 1989.
 59. Reoperations following pneumatic retinopexy (Ambler J, Meyers S, Zegarra H). American Academy of Ophthalmology Annual Meeting. New Orleans, Louisiana. October 29–November 2, 1989.

60. 1) Pneumatic retinopexy, technique, indications, and limitations. 2) Management of retinal branch vein occlusion. 3) Clinical applications of dye laser. 4) Ischemia in central retinal vein occlusion. 5) Management of retinoschisis complicated with retinal detachment. Guest lecturer, Decentro Oftalmologico Campinas. October 20–21, 1989.
61. Update on pneumatic retinopexy experience at the Cleveland Clinic. Pneumatic Retinopexy Symposium. Tampa, Florida. October 6–7, 1989.
62. 1) Update on laser photocoagulation for retinal vein occlusion. 2) Current status of retinal venous occlusive disease (central retinal vein occlusion). 3) Acute maculopathies. 4) Management of proliferative diabetic retinopathy. 5) Free paper: Failure and reoperation following pneumatic retinopexy. Pan-American Ophthalmological Society Meeting. Rio de Janeiro, Brazil. September 3–6, 1989.
63. Current indications and limitations of pneumatic retinopexy. Ohio Ophthalmological Society Meeting. Cleveland, Ohio. June 2–4, 1989.
64. Pneumatic retinopexy for retinal redetachments after buckling surgery (Zegarra H, Parker C, Meyers S). Aegean Retina. Crete, Greece. July 10–14, 1989.
65. Chronic macular detachment following otherwise successful pneumatic retinopexy (Ambler JS, Zegarra H, Meyers SM). Combined Meeting of the Retina Society and Macula Society. Boston, Massachusetts. June 21–24, 1989.
66. Clinical applications of electrophysiology. Grand Rounds St. Luke's Hospital. Cleveland, Ohio. February 3, 1989.
67. 1) Overview of macular degeneration. 2) An alternative technique to scleral buckling surgery: pneumatic retinopexy. Update on Vitreoretinal Disease. Christ Hospital. September 10, 1988.
68. Reoperation following pneumatic retinopexy. 2) CCF experience with pneumatic retinopexy. Pneumatic Retinopexy Symposium. San Diego, California. August 5–6, 1988.
69. Acute bilateral maculopathies. 2) Coordinator, Round Table on retinal vascular disease. 3) Retinal vascular disease: current therapy. Latin American Group of Angiography and Photocoagulation. Caracas, Venezuela. June 19–25, 1988.
70. A new approach for the repair of retinal detachment associated with retinoschisis. The Retina Society Meeting. Philadelphia, Pennsylvania. June 16–18, 1988.
71. 1) Complications of CRNVM treatment. 2) Laser photocoagulation for retinal tears and lattice degeneration. 3) Macular edema secondary to CRVO. Retina Research and Development Foundation Mid-Winter Course and Fluorescein Angiography Workshop. St. Louis, Missouri. February 5–6, 1988.

72. 1) Persistent macular detachment after pneumatic retinopexy. 2) Simultaneous gas-fluid exchange in nonvitrectomized eyes. Vitreous Society Meeting. St. Thomas, Virgin Islands. December 2–6, 1987.
73. Comparison of pneumatic retinopexy with alternative surgical techniques. American Academy of Ophthalmology Annual Meeting. Dallas, Texas. November 8–12, 1987.
74. Retinal venous occlusive disease — current management and treatment. Pam American Association of Ophthalmology. Santo Domingo, Dominican Republic. April 5–7, 1987.
75. Cataract surgery and intraocular lenses in diabetic patients. Vitreous Society Meeting. Palm Springs, California. December 3–6, 1986.
76. New techniques for retinal detachments. Peruvian Congress of Ophthalmology. Lima, Peru. November 2–7, 1986.
77. Retinal angiography: basic interpretation and current use of lasers in the treatment of eye disorders. Ohio Optometric Association. Huron, Ohio. October 8–9, 1986.
78. Temporary closure of retinal breaks — new approach for retinal detachment repair. Dedicatory Symposium, Department of Ophthalmology, Cleveland Clinic Foundation. Cleveland, Ohio. June 14, 1986.
79. Treatment of macular edema secondary to partial central retinal vein occlusion. Ohio Ophthalmological Society. Columbus, Ohio June 7–8, 1986.
80. Temporary closure of retinal breaks. Hilton Rocha Institute Meeting. Belo Horizonte, Brazil. April 20–21, 1986.
81. Dye lasers — use of dye lasers in ophthalmology: management of neovascularization secondary to intraocular inflammation. Latin American Group of Angiography and Photocoagulation. Belo Horizonte, Brazil. Angiography Workshop (organizer). April 18–19, 1986.
82. Common retinal disorders: recognition and management. Primary Care Conference, Cleveland Clinic Foundation. Cleveland, Ohio. February 25, 1986.
83. Ophthalmic dye lasers: A. Applications of retinal clinical trials. B. The use of different wavelengths. Joint Ophthalmology Conference of Case Western Reserve University School of Medicine and Cleveland Clinic Foundation. Cleveland, Ohio. February 15, 1986.
84. Retinal manifestations of carotid occlusive disease. Peripheral Vascular Disease Conference, Cleveland Clinic Foundation. Cleveland, Ohio. January 29, 1986.
85. Vascular occlusive disease. Erie County Medical Center case presentation. Buffalo, New York. October 17, 1985.

86. Management of retinal vascular occlusion. Buffalo Ophthalmological Society. Buffalo, New York. October 17, 1985.
87. The management of retinal venous occlusive disease. Postgraduate course, American Academy of Ophthalmology. San Francisco, California. October 3, 1985.
88. Retinal vascular diseases. Postgraduate course, XV Pan-American Congress of Ophthalmology. New Orleans, Louisiana. April 21, 1985.
89. The use of the Lincoff balloon in retinal detachment surgery. Cleveland Ophthalmological Society. Cleveland, Ohio. April 9, 1985.
90. Complications in ophthalmology: complications of intraocular lenses in diabetic patients. Postgraduate course, Cleveland Clinic Foundation. Cleveland, Ohio. November 30 to December 1, 1984.
91. 1) Evaluation of retinal ischemia by fluorescein angiography. 2) Round table on diabetic retinopathy (coordinator). 3) Intraocular lenses in diabetic patients. Latin-American Forum — Angiography and Photocoagulation. Buenos Aires, Argentina. October 24–26, 1984.
92. Intraocular lenses on diabetic patients. Retina Society Annual Meeting. Detroit, Michigan. September 13–16, 1984.
93. Symposium on diabetic retinopathy. Lima, Peru. July 6, 1984.
94. Photocoagulation of intraocular tumors. International Congress on Intraocular Tumors. Lima, Peru. July 6, 1984.
95. Lasers in ophthalmology. Peruvian-American Medical Society. Arequipa, Peru. July 2–5, 1984.
96. First Congress, Aristides de Athayde Eye Foundation, Ophthalmology 1984. Curitiba, Parana, Brazil. June 20–23, 1984.
97. Preretinal neovascularization secondary to intraocular inflammation. Cleveland Ophthalmological Society. Cleveland, Ohio. May 2, 1984.
98. Role of photocoagulation in retinal venous occlusions. Lasers in ophthalmology, postgraduate course. Cleveland Clinic Foundation. Cleveland, Ohio. December 2–3, 1983.
99. 1) Clinicophysiological evaluation of visual dysfunction. 2) Current concepts in venous occlusive disease. 3) Round table on photocoagulation. Venezuelan National Congress of Ophthalmology. Barquisimeto, Venezuela. November 20–24, 1983.

100. 1) New concepts in the diagnosis and treatment of retinal venous occlusive disease. 2) Round table on different modalities of laser therapy. XII Argentinean National Congress of Ophthalmology. Buenos Aires, Argentina. September 18–23, 1983.
101. Decreased vision: diagnosis for the non-ophthalmologist. Peruvian-American Medical Society. San Francisco, California. September 13–17, 1983.
102. 1) Retinal vein occlusion. 2) Management of the diabetic patient. 3) Course on macular diseases. XIV Pan-American Congress of Ophthalmology. Lima, Peru. July 3–8, 1983.
103. A practical course in laser eye surgery: venous occlusive disease. St. Francis General Hospital. Pittsburgh, Pennsylvania. June 4, 1983.
104. Improvement in retinal circulation after extracranial-intracranial bypass surgery for carotid occlusive disease. Association for Research in Vision and Ophthalmology Annual Meeting. Sarasota, Florida. May 1–5, 1983.
105. Management of central retinal vein occlusion. Cleveland Ophthalmological Society. Cleveland, Ohio. April 12, 1983.
106. 1) The role of laser therapy in the management of diabetic retinopathy. 2) Ocular manifestations of diabetes. Cleveland Clinic Foundation Diabetes Update Course. Cleveland, Ohio. October 27–28, 1982.
107. 1) Fluorescein angiography in diabetic retinopathy. 2) Branch vein occlusion, natural history and management. 3) Central retinal vein occlusion, types and management. Peruvian-American Medical Society. Lima, Peru. July 5–9, 1982.
108. Fluorescein angiography in neuro-ophthalmology. Latin-American Course and Symposium of Neuro-Ophthalmology. Lima, Peru. December 6–11, 1981.
109. Fluorescein angiography and laser photocoagulation. Guest of Honor, Fundacion Oftalmologica Nacional of Bogota, Colombia. Bogota, Colombia. December 4–6, 1981.
110. Symposium on Complications of Diabetes mellitus. Peruvian-American Medical Society. Bal Harbour, Florida. November 24–28, 1981.
111. Common retinopathies. Veterans Administration Hospital. Brecksville, Ohio. June 19, 1981.
112. Partial central retinal vein occlusion. Association for Research in Vision and Ophthalmology. Sarasota, Florida. April 27–May 1, 1981.
113. Retinal detachment: diagnosis and classification. Peruvian-American Medical Society. Spain. November 22–30, 1980.
114. Partial central retinal vein occlusion. 2) Photocoagulation in branch retinal vein occlusion. Retina Society. Philadelphia, Pennsylvania. October 10–11, 1980.

115. Natural course of central retinal vein occlusion. Erie Eye Clinic. Erie, Pennsylvania. April 8–9, 1980.
116. Ocular manifestations of diabetes mellitus. Hospital de la Fuerza Aerea. Lima, Peru. January 10, 1980.
117. 1) Complications of cataract surgery. 2) Retinal detachment. Universidad Federico Villareal. Lima, Peru. January 4, 1980.
118. Ocular manifestations of diabetes mellitus. Hospital de Policia. Lima, Peru. January 4, 1980.
119. Fluorescein angiography in choroidal disease. Peruvian Ophthalmological Society. Lima, Peru. December 28, 1979.
120. 1) Photocoagulation in diabetic retinopathy. 2) Retinal detachment — surgical technique. 3) Round Table on retinal disease — Case Presentation. Peruvian-American Medical Society. Lima, Peru. December 16–22, 1979
121. Retinal photocoagulation. Perspectives in ophthalmology, Cleveland Clinic Foundation. Cleveland, Ohio. December 6–7, 1979.
122. Diabetic retinopathy. Department of Endocrinology, Cleveland Clinic Foundation. Cleveland, Ohio. September 28, 1979.
123. Retinal Vascular Diseases Course. First International Congress of Surgery. Lima, Peru, July 2–5, 1979.
124. Retinal Angiography Course. Ophthalmic Photographers Society, Eastern Regional Fourth Meeting. Erie, Pennsylvania, June 16, 1979.
125. Retinal manifestations of rheumatic disease. Department of Rheumatology, Cleveland Clinic Foundation. Cleveland, Ohio. May 21, 1979.
126. Natural course of central retinal vein occlusion. Pan-American Association of Ophthalmology. Miami, Florida. February 25 to March 2, 1979.
127. Ocular electrophysiology: clinical applications. Perspectives in ophthalmology, Postgraduate course, Cleveland Clinic Foundation. Cleveland, Ohio. December 2, 1978.
128. Natural course of central retinal vein occlusion. Retina Society. Houston, Texas. November 10–11, 1978.
129. Natural course of central retinal vein occlusion. American Academy of Ophthalmology. October 24, 1978.
130. Ocular complications in cardiac surgery. Peruvian-American Medical Society. Sandom, Puerto Rico. August 2, 1978.

131. Leukemic retinopathy. American Medical Association. St. Louis, Missouri. June 21, 1978.
132. Diabetic retinopathy. Department of Endocrinology, Cleveland Clinic Foundation. Cleveland, Ohio. February 17, 1978.
133. Ocular manifestations of diabetes mellitus. Diagnosis and management of common problems in medical practice (Course for general practitioners). Cleveland Clinic Foundation. Cleveland, Ohio. May 5, 1977.
134. Usher Syndrome. Retinitis Pigmentosa Foundation, Cleveland Chapter. September 18, 1977.
135. Ocular vaso-occlusive disease. Department of Medicine, Cleveland Clinic Foundation. Cleveland, Ohio. September 16, 1977.
136. Management of diabetic retinopathy. Perspectives in Ophthalmology, Cleveland Clinic Foundation. Cleveland, Ohio. December 1976.
137. Fluorescein angiography course, Part II (Course Director). Cleveland Clinic Foundation, Cleveland, Ohio. November 3, 1976.
138. Fluorescein angiography course, Part I (Course Director). Cleveland Clinic Foundation. Cleveland, Ohio. April 8, 1976.
139. A perspective on the diagnosis and management of diabetic retinopathy. Endocrinology Postgraduate Course, Cleveland Clinic Foundation. Cleveland, Ohio. February 1976.
140. 1) Basics in fluorescein angiography. 2) Diabetic retinopathy. Cayetano Heredia University. Lima, Peru. March 1976.

PUBLICATIONS

Journal Articles

1. Chew EY, Clemons TE, Jaffe GJ, Johnson CA, Farsiu S, Lad EM, Guymer R, Rosenfeld P, Hubschman JP, Constable I, Wiley H, Singerman LJ, Gillies M, Comer G, Blodi B, Elliott D, Yan J, Bird A, Friedlander M; Macular Telangiectasia Type 2-Phase 2 CNTF Research Group. Effect of ciliary neurotrophic factor on retinal neurodegeneration in patients with macular telangiectasia type 2: a randomized clinical trial. *Ophthalmology*. 2018 Oct 4. pii: S0161-6420(18)31427-1. doi: 10.1016/j.ophtha.2018.09.041. [Epub ahead of print]
2. Yu JJ, Agrón E, Clemons TE, Domalpally A, van Asten F, Keenan TD, Cukras C, Chew EY; Age-Related Eye Disease Study 2 Research Group. Natural history of drusenoid pigment epithelial detachment associated with age-related macular degeneration: Age-Related Eye Disease Study 2 report no. 17. *Ophthalmology*. 2018

- Aug 22. pii: S0161-6420(18)31752-4. doi: 10.1016/j.ophtha.2018.08.017. [Epub ahead of print]
3. Keenan TD, Agrón E, Domalpally A, Clemons TE, van Asten F, Wong WT, Danis RG, Sadda S, Rosenfeld PJ, Klein ML, Ratnapriya R, Swaroop A, Ferris FL 3rd, Chew EY; AREDS2 Research Group. Progression of geographic atrophy in age-related macular degeneration: AREDS2 Report Number 16. *Ophthalmology*. 2018;125:1913-1928.
 4. Purnell JQ, Braffett BH, Zinman B, Gubitosi-Klug RA, Sivitz W, Bantle JP, Ziegler G, Cleary PA, Brunzell JD; DCCT/EDIC Research Group. Impact of excessive weight gain on cardiovascular outcomes in Type 1 Diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. *Diabetes Care*. 2017;40:1756-1762.
 5. DCCT/EDIC Research Group, Nathan DM, Bebu I, Hainsworth D, Klein R, Tamborlane W, Lorenzi G, Gubitosi-Klug R, Lachin JM. Frequency of evidence-based screening for retinopathy in Type 1 diabetes. *N Engl J Med*. 2017 Apr 20;376:1507-1516.
 6. Mansour AM, Sheheitli H, Kucukerdonmez C, Sisk RA, Moura R, Moschos MM, Lima LH, Al-Shaar L, Arevalo JF, Maia M, Foster RE, Kayikcioglu O, Kozak I, Kurup S, Zegarra H, Gallego-Pinazo R, Hamam RN, Bejjani RA, Cinar E, Erakgün ET, Kimura A, Teixeira A. Intravitreal dexamethasone implant in retinitis pigmentosa-related cystoid macular edema. *Retina*. 2017 Feb 17. doi: 10.1097/IAE.0000000000001542. [Epub ahead of print]
 7. Chen Z, Miao F, Paterson AD, Lachin JM, Zhang L, Schones DE, Wu X, Wang J, Tompkins JD, Genuth S, Braffett BH, Riggs AD; DCCT/EDIC Research Group, Natarajan R. Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. *Proc Natl Acad Sci U S A*. 2016;113(21):E3002-11.
 8. Lenherr SM, Clemens JQ, Braffett BH, Cleary PA, Dunn RL, Hotaling JM, Jacobson AM, Kim C, Herman W, Brown JS, Wessells H, Sarma AV; DCCT/EDIC Research Group. Glycemic control and urinary tract infections in women with type 1 diabetes: Results from the DCCT/EDIC. *J Urol*. 2016;196:1129-1135.
 9. Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the second year of the Comparison of Age-Related Macular Degeneration Treatments Trials. *Ophthalmology*. 2016;123:865-875.
 10. Shah N, Maguire MG, Martin DF, Shaffer J, Ying GS, Grunwald JE, Toth CA, Jaffe GJ, Daniel E; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Angiographic cystoid macular edema and outcomes in the

- Comparison of Age-Related Macular Degeneration Treatments Trials. *Ophthalmology*. 2016;123:858-864.
11. AREDS2 Research Group, Al-Holou SN, Tucker WR, Agrón E, Clemons TE, Sperduto RD, Ferris FL 3rd, Chew EY. The Association of statin use with cataract progression and cataract surgery: AREDS2 Report Number 8. *Ophthalmology*. 2016;123:916-917.
 12. Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, Maguire MG; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). *Ophthalmology*. 2016;123:609-616.
 13. Eny KM, Orchard TJ, Miller RG, Maynard J, Grant DM, Costacou T, Cleary PA, Braffett BH, Paterson AD; DCCT/EDIC Research Group. Caffeine consumption contributes to skin intrinsic fluorescence in type 1 Diabetes. *Diabetes Technol Ther*. 2015;17:726-734.
 14. Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, Daniel E, Jaffe GJ; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Subretinal hyperreflective material in the Comparison of Age-Related Macular Degeneration Treatments Trials. *Ophthalmology* 2015;122:1846-1853.
 15. Chew EY, Clemons TE, Peto T, Sallo FB, Ingerman A, Tao W, Singerman L, Schwartz SD, Peachey NS, Bird AC; MacTel-CNTF Research Group. Ciliary neurotrophic factor (CNTF) for macular telangiectasia Type 2 (MacTel): Results from a phase I safety trial. *Am J Ophthalmol* 2015;159:659-666.
 16. Aref AA, Scott IU, Oden NL, Ip MS, Blodi BA, VanVeldhuisen PC; SCORE Study Investigator Group. Incidence, risk factors, and timing of elevated intraocular pressure after intravitreal triamcinolone acetonide injection for macular edema secondary to retinal vein occlusion: SCORE Study Report 15. *JAMA Ophthalmol*. 2015;133:1022-1029.
 17. Altaweel MM, Daniel E, Martin DF, Mittra RA, Grunwald JE, Lai MM, Melamud A, et al; Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). *Ophthalmology* 2015;122:391-398.
 18. Simpson CL, Wojciechowski R, Oexle K, Murgia F, Portas L, Li X, Verhoeven VJ, et al; DCCT/EDIC Research Group. Genome-wide meta-analysis of myopia and hyperopia provides evidence for replication of 11 loci. *PLoS One* 2014 Sep 18;9(9):e107110. doi: 10.1371/journal.pone.0107110. eCollection 2014.
 19. Mansour AM, Arevalo JF, Al Kahtani E, Zegarra H, Abboud E, Anand R, Ahmadi H, et al. Role of intravitreal antivascular endothelial growth factor injections for choroidal

- neovascularization due to choroidal osteoma. *J Ophthalmol*. 2014;2014:210458. doi: 10.1155/2014/210458. Epub 2014 Jul 23.
20. Mansour AM, Arevalo JF, Badal J, Moorthy RS, Shah GK, Zegarra H, Pulido JS, Charbaji A, Amselem L, Lavaque AJ, Casella A, Ahmad B, Paschall JG, Caimi A, Staurenghi G. Paraproteinemic maculopathy. *Ophthalmology* 2014;121:1925-1932.
 21. Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). *JAMA Ophthalmol* 2014;132:521-527.
 22. Kim BJ, Ying GS, Huang J, Levy NE, Maguire MG; CATT Research Group. Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). *Am J Ophthalmol*. 2014;158:128-135.
 23. Nathan DM, Bayless M, Cleary P, et al; DCCT/EDIC Research Group. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. *Diabetes* 2013;62:3976-3986.
 24. Cheng CY, Schache M, Ikram MK, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions, and Complications Research Group. Nine loci for ocular axial length identified through genome-wide association studies, including shared loci with refractive error. *Am J Hum Genet* 2013;93:264-277.
 25. Jacobson AM, Braffett BH, Cleary PA, Gubitosi-Klug RA, Larkin ME; DCCT/EDIC Research Group. The long-term effects of type 1 diabetes treatment and complications on health-related quality of life: a 23-year follow-up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. *Diabetes Care* 2013;36:3131-3138.
 26. Orchard TJ, Lyons TJ, Cleary PA, et al; DCCT/EDIC Research Group. The association of skin intrinsic fluorescence with type 1 diabetes complications in the DCCT/EDIC study. *Diabetes Care* 2013;36:3146-3153.
 27. Jaffe GJ, Martin DF, Toth CA, et al; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. *Ophthalmology* 2013;120:1860-1870.
 28. Danis RP, Domalpally A, Chew EY, et al; AREDS2 Study Group. Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2). *Invest Ophthalmol Vis Sci* 2013;54:4548-4554.

29. Lopes-Virella MF, Baker NL, Hunt KJ, Cleary PA, Klein R, Virella G; DCCT/EDIC Research Group. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. *Diabetes Care* 2013;36:2317-2323.
30. Verhoeven VJ, Hysi PG, Wojciechowski R, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Genome-wide meta-analyses of multi-ancestry cohorts identify multiple new susceptibility loci for refractive error and myopia. *Nat Genet* 2013;45:314-318.
31. Hagstrom SA, Ying GS, Pauer GJ, et al; Comparison of AMD Treatments Trials Research Group. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). *Ophthalmology* 2013;120:593-599.
32. Ying GS, Huang J, Maguire MG, et al; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. *Ophthalmology* 2013 Jan;120:122-129.
33. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. *Ophthalmology* 2012;119:1388-1398.
34. Lopes-Virella MF, Baker NL, Hunt KJ, Lyons TJ, Jenkins AJ, Virella G; DCCT/EDIC Study Group. High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes. *Diabetes Care* 2012;35:1333-1340.
35. DCCT/EDIC Research Group, de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. *N Engl J Med* 2011;365:2366-2376.
36. Haller JA, Bandello F, Belfort R Jr, et al; Ozurdex GENEVA Study Group, Li J. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. *Ophthalmology* 2011;118:2453-2460
37. Sallo FB, Leung I, Chung M, Wolf-Schnurrbusch UE, Dubra A, Williams DR, Clemons T, Pauleikhoff D, Bird AC, Peto T; MacTel Study Group. Retinal crystals in type 2 idiopathic macular telangiectasia. *Ophthalmology* 2011;118:2461-2467.
38. Chan CK, Ip MS, Vanveldhuisen PC, Oden NL, Scott IU, Tolentino MJ, Blodi BA; SCORE Study Investigator Group. SCORE Study Report #11. Incidences of

- neovascular events in eyes with retinal vein occlusion. *Ophthalmology* 2011;118:1364-1372.
39. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration.. *N Engl J Med* 2011 May 19;364:1897-1908. Epub 2011 Apr 28.
 40. de Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Sun W, Zinman B, Brunzell JD; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group, White NH, Danis RP, Davis MD, Hainsworth D, Hubbard LD, Nathan DM. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. *Arch Intern Med* 2011;171:412-420.
 41. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. *Ophthalmology* 2010;117:1134-1146.
 42. Chen W, Stambolian D, Edwards AO, Branham KE, Othman M, Jakobsdottir J, Tosakulwong N, Pericak-Vance MA, Campochiaro PA, Klein ML, Tan PL, Conley YP, Kanda A, Kopplin L, Li Y, Augustaitis KJ, Karoukis AJ, Scott WK, Agarwal A, Kovach JL, Schwartz SG, Postel EA, Brooks M, Baratz KH, Brown WL; Complications of Age-Related Macular Degeneration Prevention Trial Research Group, Brucker AJ, Orlin A, Brown G, Ho A, Regillo C, Donoso L, Tian L, Kaderli B, Hadley D, Hagstrom SA, Peachey NS, Klein R, Klein BE, Gotoh N, Yamashiro K, Ferris Iii F, Fagerness JA, Reynolds R, Farrer LA, Kim IK, Miller JW, Cortón M, Carracedo A, Sanchez-Salorio M, Pugh EW, Doheny KF, Brion M, Deangelis MM, Weeks DE, Zack DJ, Chew EY, Heckenlively JR, Yoshimura N, Iyengar SK, Francis PJ, Katsanis N, Seddon JM, Haines JL, Gorin MB, Abecasis GR, Swaroop A. Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. *Proc Natl Acad Sci U S A* 2010 Apr 20;107:7401-7406.
 43. Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, Antoszyk AN; SCORE Study Investigator Group. SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design. *Am J Ophthalmol* 2009;148:725-732.
 44. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. *Arch Ophthalmol* 2009;127:1115-1128.
 45. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with

- macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. *Arch Ophthalmol* 2009;127:1101-1114.
46. Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Figueroa M, Antoszyk A, Elman M and the SCORE Study Investigator Group. SCORE Study Report 3: Study design and baseline characteristics. *Ophthalmology* 2009;116:1770–1777.
 47. Ying GS, Maguire MG, Alexander J, Martin RW, Antoszyk AN; Complications of Age-related Macular Degeneration Prevention Trial Research Group. Description of the Age-Related Eye Disease Study 9-step severity scale applied to participants in the Complications of Age-related Macular Degeneration Prevention Trial. *Arch Ophthalmol* 2009;127:1147-1151.
 48. Cordell WH, Maturi RK, Costigan TM, Marmor MF, Weleber RG, Coupland SG, Danis RP, McGettigan JW Jr, Antoszyk AN, Klise S, Sides GD; ERG Testing During Chronic PDE5 Inhibitor Administration (ERG-PDE5i) Consortium. Retinal effects of 6 months of daily use of tadalafil or sildenafil. *Arch Ophthalmol* 2009;127:367-373.
 49. Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Figueroa M, Harrington MW; Macular Telangiectasia Research Group. The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project. *Invest Ophthalmol Vis Sci* 2008;49:4340-4346.
 50. Ying G-S, Maguire M, Liu C, Antoszyk A, Complications of Age-related Macular Degeneration Prevention Trial Research Group. Night vision symptoms and progression of age-related macular degeneration (AMD) in the Complications of AMD Prevention Trial. *Ophthalmology* 2008;115:1876-1882.
 51. Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group. Risk factors for choroidal neovascularization and geographic atrophy in the complications of age-related macular degeneration prevention trial. *Ophthalmology* 2008;115:1474-1479, 1479.e1-6. Epub 2008 May 27.
 52. Maguire MG, Alexander J, Fine SL; Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group. Characteristics of choroidal neovascularization in the complications of age-related macular degeneration prevention trial. *Ophthalmology* 2008;115:1468-1473, 1473.e1-2. Epub 2008 May 16.
 53. Macugen AMD Study Group, Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. *Ophthalmology* 2007;114:1702-1712.
 54. Rosenfeld PJ, Boyer DS, Bressler NM, Fish G, Grizzard WS, Hao Y, Hnik P, Hudson HL, Singerman L, Slakter JS; VALIO Study Group. Verteporfin therapy of subfoveal

- occult choroidal neovascularization in AMD using delayed light application: one-year results of the VALIO Study. *Am J Ophthalmol* 2007;144:970-972.
55. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreal dexamethasone drug delivery system in patients with persistent macular edema. *Arch Ophthalmol* 2007;125:309-317.
 56. Russell SR, Hudson HL, Jerdan JA; Anecortave Acetate Clinical Study Group. Anecortave acetate for the treatment of exudative age-related macular degeneration--a review of clinical outcomes. *Surv Ophthalmol* 2007;52 Suppl 1:S79-90.
 57. Complications of Age-related Macular Degeneration Prevention Trial Research Group. Laser treatment in patients with bilateral large drusen: The Complications of Age-Related Macular Degeneration Prevention Trial. *Ophthalmology* 113:1974-1986, 2006.
 58. Melamud A, Shen GQ, Chung D, Xi Q, Simpson E, Li L, Peachey NS, Zegarra H, Hagstrom SA, Wang QK, Traboulsi EI. Mapping a new genetic locus for X linked retinitis pigmentosa to Xq28. *J Med Genet* 2006;43:e27
 59. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. *N Engl J Med* 355:1432-1444, 2006.
 60. PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the protein kinase C {beta} inhibitor diabetic retinopathy study (PKC-DRS) multicenter randomized clinical trial. *Diabetes* 2005; 54:2188-2197.
 61. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. *N Engl J Med* 2004 Dec 30;351:2805-2816.
 62. Al-Khayer K, Hagstrom S, Pauer G, Zegarra H, Sears J, Traboulsi EI. Thirty-year follow-up of a patient with leber congenital amaurosis and novel RPE65 mutations. *Am J Ophthalmol* 2004;137:375-377.
 63. Hawkins BS, Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. *Am J Ophthalmol* 2004;138:936-951.
 64. Maguire M; Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). *Ophthalmology* 2004;111:1307-1316.

65. Collaborative Ocular Melanoma Study Group. Ten-year follow-up of fellow eyes of patients enrolled in Collaborative Ocular Melanoma Study (COMS) randomized trials. COMS Report No. 22. *Ophthalmology* 111:966-976, 2004.
66. Bressler SB, Pieramici DJ, Koester JM, Bressler NM for the TAP Study Group. Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevant to management – TAP report No. 6. *Arch Ophthalmol* 2004 Mar;122:325-329.
67. Complications of Age-related Macular Degeneration Prevention Trial Study Group. The Complications of Age-related Macular Degeneration Prevention Trial (CAPT): rationale, design, and methodology. *Clinical Trials* 2004; 1:91-107.
68. Azab M, Benchaboune M, Blinder KJ, et al; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group; Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. *Retina* 2004;24:1-12.
69. Collaborative Ocular Melanoma Study Group. Comparison of clinical, echographic, and histopathological measurements from eyes with medium-sized choroidal melanoma in the collaborative ocular melanoma study: COMS Report No. 21. *Arch Ophthalmol* 121:1163-1171, 2003.
70. Collaborative Ocular Melanoma Study Group. Trends in size and treatment of recently diagnosed choroidal melanoma, 1987-1997: findings from patients examined at collaborative ocular melanoma study (COMS) centers: COMS Report No. 20. *Arch Ophthalmol* 121:1156-1162, 2003.
71. Melia M, Moy CS, Reynolds SM, Cella D, Murray TG, Hovland KR, Hayman JA, Mangione CM, the Collaborative Ocular Melanoma Study-Quality of Life Study Group. Development and validation of disease-specific measures for choroidal melanoma: COMS-QOLS report No. 2. *Arch Ophthalmol* 121:1010-1020, 2003.
72. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna SP, Robertson SM, Russell S, Singerman L, Slakter JS, Yannuzzi L, Zilliox P; Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. *Ophthalmology* 2003;110:2372-2383.
73. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JJ, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA; Verteporfin In Photodynamic Therapy Study Group.

- Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial – VIP Report No. 3. *Ophthalmology* 2003;110:667-673.
74. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger S, Luna S, Robertson SM, Russell S, Singerman L, Slakter JS, Sullivan EK, Yannuzzi L, Ziliox P; The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. *Retina* 2003;23:14-23.
 75. Straatsma BR, Diener-West M, Caldwell R, Engstrom RE; Collaborative Ocular Melanoma Study Group. Mortality after deferral of treatment or no treatment for choroidal melanoma. *Am J Ophthalmol* 136:47-54, 2003.
 76. Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS Report No. 19. *Ophthalmology* 109:2197-2206, 2002.
 77. Rubin GS, Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Effects of verteporfin therapy on contrast sensitivity: results from the Treatment of Age-related macular degeneration with Photodynamic therapy (TAP) Investigation – TAP Report No. 4. *Retina* 2002;22:536-544.
 78. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration. Additional information regarding baseline lesion composition's impact on vision outcomes – TAP Report No. 3. *Arch Ophthalmol* 2002;120:1443-1454.
 79. Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M, Singerman LJ, Slakter JS, Strong A, Vannier S, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration. Three-year results of an open-label extension of 2 randomized clinical trials – TAP report No. 5. *Arch Ophthalmol* 2002;120:1307-1314.
 80. Verteporfin Roundtable 2000 And 2001 Participants, Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators, and Verteporfin in Photodynamic Therapy (VIP) Study Group Principal Investigators Group. Guidelines for using verteporfin (Visudyne®) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. *Retina* 2002;22:6-18.

81. Collaborative Ocular Melanoma Study Group. Sociodemographic and clinical predictors of participation in two randomized trials: Findings from the Collaborative Ocular Melanoma Study. COMS Report No. 7. *Controlled Clin Trials* 22:526-537, 2001.
82. Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of 1-125 brachytherapy for choroidal melanoma, III. Initial mortality findings. COMS Report No. 18. *Arch Ophthalmol* 119:969-982, 2001.
83. Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of 1-125 brachytherapy for choroidal melanoma, II: Characteristics of patients enrolled and not enrolled. COMS Report No. 17. *Arch Ophthalmol* 119:951-965, 2001.
84. Grostern RJ, Slusker Shternfeld I, Bacus SS, Gilchrist K, Zimbric ML, Albert DM; Collaborative Ocular Melanoma Study Group. Absence of type I estrogen receptors in choroidal melanoma: analysis of Collaborative Ocular Melanoma Study (COMS) eyes. *Am J Ophthalmol* 131:788-791, 2001.
85. The Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years. COMS Report No. 16. *Ophthalmology* 108:348-366, 2001.
86. The Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS Report No. 15. *Arch Ophthalmol* 119:670-676, 2001.
87. Moy CS, Albert DM, Diener-West M, McCaffrey LD, Scully RE, Willson JK; The Collaborative Ocular Melanoma Study Group, prepared by COMS Mortality Coding Committee. Cause-specific mortality coding. Methods in the Collaborative Ocular Melanoma Study. COMS Report No. 14. *Control Clin Trials* 22:248-262, 2001.
88. Doft BH, Wisniewski SR, Kelsey SF, Fitzgerald SG; Endophthalmitis Vitrectomy Study Group. Diabetes and postoperative endophthalmitis in the endophthalmitis vitrectomy study. *Arch Ophthalmol* 2001;119:650-656.
89. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. Verteporfin in Photodynamic Therapy Report 2. *Am J Ophthalmol* 2001;131:541-560.
90. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: One-

- year results of a randomized clinical trial. VIP report #1. *Ophthalmology* 2001;108:841-852.
91. Sanislo SR, Lowder CY, Kaiser PK, Gutman FA, Zegarra H, Dodds EM, Dailey JP, Meisler DM, Cunningham ET. Corticosteroid therapy for optic disc neovascularization secondary to chronic uveitis. *Am J Ophthalmol* 2000;130:724-731.
 92. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials. TAP report #2. *Arch Ophthalmol* 2001;119:198-207.
 93. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials—TAP Report 1. *Arch Ophthalmol* 1999;117:1329-1345.
 94. COMS Quality of Life Study Group. Quality of life assessment in the collaborative ocular melanoma study: design and methods. COMS-QOLS Report No. 1. *Ophthalmic Epidemiol* 6:5-17, 1999.
 95. Collaborative Ocular Melanoma Study Group. Echography (ultrasound) procedures for the Collaborative Ocular Melanoma Study. COMS Report No. 12. *J Ophthalm Nurs Technol* Part I 18:143-149, Part II 18:219-232, 1999.
 96. Choroidal Neovascularization Prevention Trial Research Group. Choroidal neovascularization in the choroidal neovascularization prevention trial. *Ophthalmology* 1998;105:1364-1372.
 97. Collaborative Ocular Melanoma Study Group: The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma III. Local complications and observations following enucleation. COMS Report No. 11. *Am J Ophthalmol* 126: 362-372, 1998.
 98. The Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. II. Initial mortality findings. COMS Report No. 10. *Am J Ophthalmol* 125:779-796, 1998.
 99. The Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. I. Characteristics of patients enrolled and not enrolled. COMS Report No. 9. *Am J Ophthalmol* 125:767-778, 1998.
 100. The Collaborative Ocular Melanoma Study Group. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS Report No. 6. *Am J Ophthalmol* 125:745-766, 1998.

101. Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in eyes with large drusen. Short-term effects seen in a pilot randomized clinical trial. *Ophthalmology* 1998;105:11-23.
102. The Collaborative Ocular Melanoma Study Group. Factors predictive of growth and treatment of small choroidal melanoma. COMS Report No. 5. *Arch Ophthalmol* 115:1537-1544, 1997.
103. Grossniklaus HE, Albert DM, Green WR, Conway BP, Hovland KR for the Collaborative Ocular Melanoma Study Group. Clear cell differentiation in choroidal melanoma. COMS report no. 8. *Arch Ophthalmol* 115:894-898, 1997.
104. The Collaborative Ocular Melanoma Study Group. Mortality in patients with small choroidal melanoma. COMS Report No. 4. *Arch Ophthalmol* 115:886-893, 1997.
105. Pharmacological Therapy for Macular Degeneration Study Group. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. *Arch Ophthalmol* 1997;115:865-872.
106. Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. *Arch Ophthalmol* 1997;115:486-91; erratum in *Arch Ophthalmol* 1997;115:1275.
107. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. *Arch Ophthalmol* 1995;113:1479-1496.
108. Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion: The Central Vein Occlusion Study Group N Report. *Ophthalmology* 1995; 102:1434-1444.
109. Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: The Central Vein Occlusion Study Group M Report. *Ophthalmology* 1995;102:1425-1433.
110. Central Vein Occlusion Study Group. Baseline and early natural history report: The Central Vein Occlusion Study (CVOS). *Arch Ophthalmol* 1993;111:1087-1095.
111. Collaborative Ocular Melanoma Study Group. Design and methods of a clinical trial for a rare condition: the Collaborative Ocular Melanoma Study. COMS Report No. 3. *Controlled Clin Trials* 14:362-391, 1993.
112. Collaborative Ocular Melanoma Study Group. Complications of enucleation surgery. COMS Report No. 2. In Franklin RM (ed). *Proceedings of the Symposium on Retina and*

- Vitreous*, New Orleans Academy of Ophthalmology. New York: Kugler Publications, 1993, pp 181-190.
113. Fong ACO, Schatz H, McDonald HR, Burton TC, Maberley AL, Joffe L, Zegarra H, Nadel AJ, Johnson RN. Central retinal vein occlusion in young adults (papillophlebitis). *Retina* 12:3-11, 1992.
 114. Zegarra H. Summary and comment on: Sprafka JM, Frische TL, Baker R, Kurth D, Whipple D. Prevalence of undiagnosed eye disease in high-risk diabetic individuals. *Diabetes Spectrum* 4:163-164, 1991.
 115. Vestal KP, Meyers SM, Zegarra H. Retinal detachment as a complication of retrobulbar anesthesia. *Can J Ophthalmology* 26:32-33, 1991.
 116. Marcus DM, Minkovitz JB, Wardwell SD, Albert DM for the Collaborative Ocular Melanoma Study Group. The value of nucleolar organizer regions in uveal melanoma. *Am J Ophthalmol* 110:527-534, 1990.
 117. Collaborative Ocular Melanoma Study Group. Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS Report No. 1. *Arch Ophthalmol* 108:1268-1273, 1990.
 118. Ambler JS, Zegarra H, Meyers SM. Chronic macular detachment following otherwise successful pneumatic retinopexy. *Retina* 10:125-130, 1990.
 119. Ambler JS, Zegarra H, Meyers SM, Paranandi L. Reoperations and visual results after failed pneumatic retinopexy. *Ophthalmology* 97:786-790, 1990.
 120. Ambler JS, Zegarra H, Meyers SM. Delayed reabsorption of subretinal fluid after pneumatic retinopexy (letter; comment on Chan CK, Wessels IF, Delayed reabsorption of subretinal fluid after pneumatic retinopexy. *Ophthalmology* 96:1691-1700, 1989). *Ophthalmology* 97:695 1990.
 121. Ambler JS, Meyers SM, Zegarra H, Gutman FA. The management of retinal detachment complicating degenerative retinoschisis. *Am J Ophthalmol* 107:171-176, 1989.
 122. Straatsma BR, Fine SL, Earle JD, Hawkins BS, Diener-West M, McLaughlin JA, Collaborative Ocular Melanoma Study Research Group. Enucleation versus plaque irradiation for choroidal melanoma. *Ophthalmology* 95:1000-1004, 1988.
 123. McAllister IL, Meyers SM, Zegarra H, Gutman FA, Zakov ZN, Beck GJ. Comparison of pneumatic retinopexy with alternative surgical techniques. *Ophthalmology* 95:877-883, 1988.
 124. Allen KM, Meyers SM, Zegarra H. Nanophthalmic uveal effusion. *Retina* 8:145-147, 1988.

125. McAllister IL, Zegarra H, Meyers SM, Gutman FA. Treatment of retinal detachments with multiple breaks by pneumatic retinopexy. *Arch Ophthalmol* 105:913-916, 1987.
126. McDonald HR, Abrams GW, Irvine AR, Sipperley JO, Boyden BS, Flore JV, Zegarra H. The management of subretinal gas following attempted pneumatic retinal reattachment. *Ophthalmology* 94:319-326, 1987.
127. Rabon RJ, Louis GJ, Zegarra H, Gutman FA. Acute bilateral posterior angiopathy with influenza A viral infection. *Am J Ophthalmol* 103:289-293, 1987.
128. Meyers SM, Zegarra H, Nguyen DM, Skipper GJ. Simultaneous external subretinal fluid drainage and intravitreal gas injection in nonvitrectomized eyes with a special 27-gauge needle. *Arch Ophthalmol* 104:1394-1395, 1986.
129. Stern RM, Zakov ZN, Zegarra H, Gutman FA. Multiple recurrent serosanguineous retinal pigment epithelial detachments in black women. *Am J Ophthalmol* 100:560-569, 1985.
130. Standefer M, Little JR, Tomsak R, Furlan AJ, Zegarra H, Williams G. Improvement in the retinal circulation after superficial temporal to middle cerebral artery bypass. *Neurosurgery* 16:525-529, 1985.
131. Ludwig IH, Zegarra H, Zakov ZN. The acute retinal necrosis syndrome: possible herpes simplex retinitis? *Ophthalmology* 91:169-174, 1984.
132. Gutman FA, Zegarra H. Macular edema secondary to occlusion of the retinal veins. *Surv Ophthalmol* 28 Suppl:462-470, 1984.
133. Aaby AA, Zegarra H. The tourniquet test in identifying diabetic retinopathy [letter] *JAMA* 250:1843-1844, 1983.
134. Zegarra H, Gutman FA, Zakov N, Carim M. Partial occlusion of the central retinal vein. *Am J Ophthalmol* 96:330-337, 1983.
135. Zegarra H, Gutman FA, Zakov N, Carim M. Partial central retinal vein occlusion. *Invest Ophthalmol Vis Sci* 20 (Suppl):142, 1981.
136. Dreyer WB Jr, Zegarra H, Zakov ZN, Gutman FA. Sympathetic ophthalmia: a case report. *Am J Ophthalmol* 92:816-823, 1981.
137. Lowder CY, Gutman FA, Zegarra H, Zakov ZN, Lowder J, Clough JD. Macular and paramacular detachment of the neurosensory retina associated with systemic diseases. *Trans Am Ophthalmol Soc* 79:347-370, 1981.
138. Gutman FA, Zegarra H, Rauer A, Zakov N. Photocoagulation in retinal branch vein occlusion. *Ann Ophthalmol* 13:1359-1363, 1981.

139. Wilhelm JL, Zakov ZN, Weinstein MA, Berlin LA, Zegarra H, Gutman FA. Localization of suspected intraocular foreign bodies with a modified Delta 2020 scanner. *Ophthalmic Surgery* 12:633-641, 1981.
140. Gutman FA, Zegarra H, Rauer A, Zakov N. Photocoagulation in retinal branch vein occlusion. *Trans Am Ophthalmol Soc* 78:156-166, 1980.
141. Sakamoto DK, Zegarra H, Gutman FA, Zakov ZN. Silicone sponge implant in combination with episcleral implant for retinal detachment surgery. *Ophthalmic Surg* 11:712-718, 1980.
142. Zegarra H, Gutman FA, Conforto J. The natural course of central retinal vein occlusion. *Ophthalmology* 86:1931-1942, 1979.
143. Zakov ZN, Rich LS, Zegarra H, Gutman FA. Differential diagnosis of preretinal neovascularization. *Perspect in Ophthalmol* 2(3), September 1978.
144. Zegarra H, Gutman FA. Ocular complications in cardiac surgery. *Perspect in Ophthalmol* 2(3), September 1978.
145. Gutman FA, Zegarra H, Zakov ZN. Retinal branch vein occlusion. *Perspect in Ophthalmol* 1(1), March 1977.
146. Gutman FA, Zegarra H. Retinal detachment secondary to retinal branch vein occlusions. *Trans Am Acad Ophthalmol Otolaryngol* 81:491-496, 1976.
147. Gutman FA, Zegarra H. The natural course of temporal retinal branch vein occlusion. *Trans Am Acad Ophthalmol Otolaryngol* 78:OP178-192, 1974.
148. Gutman FA, Zegarra H. Ocular complications in cardiac surgery. *Surg Clin North Am* 51:1095-1103, 1971.

Book Chapters

1. Pendergast SD, Singerman LJ, Niffenegger JH, Zegarra H. Laser treatment for proliferative diabetic retinopathy. In Saer JB (ed.). *Vitreo-Retinal and Uveitis Update. Proceedings of the New Orleans Academy of Ophthalmology Symposium*. The Hague: Kugler Publications, 1998.
2. Zegarra H, Singerman LJ, Pendergast SD. Central retinal vein occlusion. In Saer JB (ed.). *Vitreo-Retinal and Uveitis Update. Proceedings of the New Orleans Academy of Ophthalmology Symposium*. The Hague: Kugler Publications 1998, pp 259-267.
3. Zegarra H, Finkelstein D, Singerman LJ, Niffenegger JH. Laser management of branch and central retinal vein occlusions. In Singerman LJ, Coscas G (eds). *Current Techniques in Ophthalmic Laser Surgery*. Philadelphia: Current Medicine, 1999, pp 67-76.

4. Singerman LJ, Addiego R, Lamkin JC, Zegarra H. Laser therapy for other macular diseases. In Karlin DB (ed). *Lasers in Ophthalmology*. Cambridge, Mass: Blackwell Scientific Publications, Inc, 1995.
5. Singerman LJ, Addiego R, Lamkin JC, Zegarra H. Laser therapy for choroidal neovascularization. In Karlin DB (ed). *Lasers in Ophthalmology*. Cambridge, Mass: Blackwell Scientific Publications, Inc, 1995.
6. Zegarra H, Ambler JS, Meyers SM. Reoperations for pneumatic retinopexy failures. In Tornambe PE, Grizzard WS (eds). *Pneumatic Retinopexy: A Clinical Symposium*. Chicago, Greenwood Publishing, 1989, pp 102-107.
7. Zegarra H, Meyers SM, McAllister I. Clinical experience: Cleveland, Ohio. In Tornambe PE, Grizzard WS (eds). *Pneumatic Retinopexy: A Clinical Symposium*. Chicago, Greenwood Publishing, 1989, pp 142-147.
8. Tomsak RL, Zegarra H, Gutman FA. Bilateral central scotomas from macular ischemia. In Smith JL (ed). *Neuro-ophthalmology Focus – 1982*. New York, Masson, 1982, pp 99-104.
9. Gutman FA, Zegarra H, Zakov ZN. Temporal retinal branch vein occlusion: correlation of fluorescein angiography and visual prognosis. In Cant JS (ed): *Vision and Circulation*. London, Henry Kimpton, 1976, p 43.

Posters

1. Daroszewski D, Coney J, Schartman J, Miller D, Rao L, Zegarra H. Efficacy of the 0.19 mg fluocinolone acetonide (FAc) 4 (Iluvien®) in a multiphysician, single-practice setting – the Cleveland experience. Poster B0155, Association for Research in Vision and Ophthalmology Annual Meeting. Vancouver, British Columbia, Canada, April-May 2019.
2. Liu J, Coney J, Schartman J, Miller DG, Zegarra H, Rao L. Fluocinolone acetonide (FAc) 0.2 mg intravitreal implant in the treatment of diabetic macular edema (DME). Poster 4816 - C0174, Association for Research in Vision and Ophthalmology Annual Meeting, May 2018.
3. Sharma MC, Miller DG, Zakov ZN, Pendergast SD, Novak MA, Zegarra H, Singerman LJ. Results of the surgical management of idiopathic epiretinal membrane. Scientific Poster 472, American Academy of Ophthalmology Annual Meeting, October 2005.
4. Cole L, Zakov ZN, Haik B, Meisler DM, Zegarra H, Berlin J, Berlin L, Ellsworth R, Chang S. Poster, The varied presentation of cutaneous malignant melanoma metastatic to the eye and orbit. American Academy of Ophthalmology Annual Meeting, San Francisco, California, September 29 to October 3, 1985.

5. Gutman FA, Zegarra H, Zakov ZN, Ross D. Poster, International Congress of Ophthalmology, San Francisco, California, November 1–2, 1984.
6. Ludwig I, Zegarra H, Zakov ZN. The acute retinal necrosis syndrome. Herpes simplex retinitis? Poster, American Academy of Ophthalmology Annual Meeting, Chicago, Illinois, October 30 to November 3, 1983.
7. Albanese U, Zegarra H, Zakov ZN. Xenon endophotocoagulation and neovascular glaucoma in postvitrectomy diabetic eyes. Poster, Association for Research in Vision and Ophthalmology Annual Meeting, Sarasota, Florida, May 2–5, 1983; Pan American Congress of Ophthalmology, Lima, Peru, July 3–8, 1983.